Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
June 13, 2024 21:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547...
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2024 20:49 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)
June 13, 2024 19:58 ET
|
Opthea Limited
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024 MELBOURNE,...
Vaxart Announces $40 Million Underwritten Offering of Common Stock
June 13, 2024 19:07 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering...
ONWARD® Medical Announces Results of Annual General Meeting of Shareholders
June 13, 2024 17:36 ET
|
ONWARD Medical NV
ONWARD® Medical Announces Results of Annual General Meeting of Shareholders: shareholders approve all proposed resolutions
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
June 13, 2024 17:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced the...
Gain Therapeutics Announces Proposed Public Offering
June 13, 2024 16:44 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market...
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
June 13, 2024 16:40 ET
|
Dyne Therapeutics, Inc.
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Dyne...
Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update
June 13, 2024 16:20 ET
|
Enzo Biochem, Inc.
FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024. ...
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
June 13, 2024 16:15 ET
|
Vaxart, Inc.
— 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — — Vaxart anticipates initiating enrollment as early...